ACE inhibitor or ARB therapy for LVSD (outpatient and inpatient setting) Percentage of patients aged 18 y with a diagnosis of HF with a current or prior LVEF <40% who were prescribed ACE inhibitor or ARB therapy either within a 12-mo period when seen in the outpatient setting or at hospital discharge Inpatient and outpatient  Individual practitioner  Facility 8. Counseling about ICD implantation for patients with LVSD on combination medical therapyyz Percentage of patients aged 18 y with a diagnosis of HF with current LVEF 35% despite ACE inhibitor/ARB and beta-blocker therapy for at least 3 mo who were counseled about ICD placement as a treatment option for the prophylaxis of sudden death Outpatient Individual practitioner 9. Postdischarge appointment for HF patients Percentage of patients, regardless of age, discharged from an inpatient facility to ambulatory care or home health care with a principal discharge diagnosis of HF for whom a follow-up appointment was scheduled and documented, including location, date, and time for a follow-up office visit or home health visit (as specified) Inpatient Facility N.B., Regarding test measure no. 8, implantation of an ICD must be consistent with published guidelines. This measure is intended to promote counseling only. *Refer to the complete measures for comprehensive information, including measure exception. yTest measure designated for use in internal quality improvement programs only. These measures are not appropriate for any other purpose (e.g., pay for performance, physician ranking, or public reporting programs). zNew measure. ACCF indicates American College of Cardiology Foundation; ACE, angiotensin-converting enzyme; AHA, American Heart Association; AMA-PCPI, American Medical AssociationPhysician Consortium for Performance Improvement; ARB, angiotensin-receptor blocker; HF, heart failure; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; and LVSD, left ventricular systolic dysfunction. Adapted from Bonow et al. (383). JACC Vol. 62, No. 